WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) reported fourth-quarter profit of $107 million or $0.07 per share, lower than $236 million or $0.15 per share a year ago. The recent quarter results included acquisition- and divestiture-related net credits, litigation-, and restructuring-related charges, discrete tax items and amortization expense, of $90 million, or $0.06 per share. Adjusted earnings per share for the quarter was $0.13, versus $0.20 in the prior-year quarter. On average, 25 analysts polled by Thomson Reuters expected the company to report earnings of $0.08 per share. Analysts' estimates typically exclude special items. Net sales declined to $1.85 billion from last year's $2 billion. Analysts estimated revenues of $1.91 billion. Excluding the impact of foreign currency and sales from divested businesses, sales were down 5 percent as compared to the prior period. Cardiac Rhythm Management revenues for the quarter dropped 15% to $482 million from $564 million a year ago. Looking ahead, the Company estimates sales for the first quarter of 2012 in a range of $1.825 to $1.900 billion. Adjusted earnings, excluding acquisition- and restructuring-related charges; and amortization expense, are estimated in a range of $0.11 to $0.14 per share. Analysts expect the company to earn $0.11 per share, on revenues of $1.90 billion. The company also estimates sales for the full year 2012 in a range of $7.300 to $7.700 billion. Adjusted earnings, excluding acquisition- and restructuring-related charges; and amortization expense, are estimated in a range of $0.60 to $0.70 per share. Analysts expect the company to earn $0.46 per share, on revenues of $7.65 billion.
Copyright RTT News/dpa-AFX
© 2012 AFX News
